Gilead Sciences (GILD) is under severe pressure and many investors don’t think it’ll ever come back which is almost always an excellent contrarian buying signal, explains Keith Fitz-Gerald — principal of the Fitz-Gerald Group and editor of One Bar Ahead, a digital magazine exclusively for individual investors and traders.
The company popped nearly a year ago last March when Covid-19 broke and, in doing so, set a new 52-week high of $85.97 based on investor expectations associated with Remdesivir. Since then, Gilead’s been scrapping along at bottom of the barrel prices.
I think the stock could easily return to $85 a share within the next 12-24 months and top $100+ for a double in 36 months. Like so many stocks I am evaluating at the moment, this company has a lot going for it that the markets do not recognize immediately but will.
Gilead is what I call a “virus+” investment. Consider:
• Gilead has a massive oncology portfolio including Yescarta and Tecartus which may produce $2+ billion in sales with additional treatments and approvals on tap in 2021. That’s in addition to what could be a $10 billion oncology portfolio a decade from now if company data proves out like I think it will.
• The company’s HIV treatment is the industry’s leading choice and, despite a Federal HHS lawsuit, a significant revenue driver with sales of $20+ billion.
• Gilead spent $27 billion acquiring five significant choices in 2020 including Forty Seven, Pionyr Immunotherapeutics, Tizona Therapeutics, Immunomedics and Myr GmbH that should provide a powerful launching point for entirely new drug channels.
MoneyShow’s Top 100 Stocks for 2021
The top performing newsletter advisors and analyst are back, and they just released their best stock ideas for 2021. Get your FREE copy of MoneyShow’s 2021 Top Picks report here and see why the nation's leading investment experts believe these stocks will significantly outperform the market in 2021.
• All of this comes at a time when Gilead’s scientists are learning a lot from the Covid-19 fight that can potentially be applied to the company’s entire portfolio.
• Yield is a healthy 4.79% as of this writing and an appealing choice for income starved investors at a time when rates will remain low for the foreseeable future.
• The PEG ratio is a very appealing 0.42 which suggests extraordinary value for expected growth.
Action to Take: Gilead could fall further if investors stay focused on Covid-19 vaccines but that’s a tremendous opening in the scheme of things to my way of thinking. Cancer isn’t going away any time soon. Anything under $60 is a serious bargain in the offering with the right perspective and time frame.
Options-savvy investors seeking an even more aggressive opening could consider selling cash secured puts as an alternative in the $50 - $55 range. (Disclosures: Keith owns and trades shares of Gilead as do members of his family.)